Decreased viability was shown to be due to the induction of a G2/M cell cycle arrest via CHK1 phosphorylation, revealing TIMELESS as a potential target for colon cancer therapy, particularly in combination with other DNA damaging agents or CHK1/Wee1 inhibition [18]. This evidence concerns the gene CHEK1 and colonic neoplasm.